Is Compounded Semaglutide Still Legal to Get Online in 2026?
Large-scale compounded semaglutide is now restricted after the FDA resolved the shortage and moved to close the 503B pathway. Here's exactly what changed — and what your options are today.
The direct answer
As of 2026, routine large-scale compounded semaglutide is no longer legally available the way it was during the shortage. The FDA declared the semaglutide shortage resolved in February 2025 and wound down compounding enforcement discretion for 503A and 503B facilities shortly after. On May 1, 2026, the FDA proposed removing semaglutide from the 503B bulks list entirely, citing no clinical need (91 FR 23431). One narrow exception remains: a state-licensed (503A) pharmacy can still compound semaglutide for an individual patient when a prescriber documents a specific clinical need an FDA-approved product can't meet — but mass-produced copies are no longer permitted. For most patients in 2026, the legitimate paths are FDA-approved brand-name semaglutide (Wegovy or Ozempic) or a clinically appropriate alternative prescribed through a licensed provider.
Regulatory history
What Changed, and When
The window for large-scale compounded semaglutide closed over the course of 2025. Here is the exact sequence.
| Date | What happened |
|---|---|
| Feb 2025 | FDA declared the semaglutide shortage resolved |
| Early 2025 | Enforcement discretion wound down for 503A state-licensed pharmacies |
| Mid 2025 | Enforcement discretion ended for 503B outsourcing facilities — mass compounding effectively ends |
| May 1, 2026 | FDA proposed excluding semaglutide from the 503B bulks list ("no clinical need" finding) — Federal Register docket 2026-08552, 91 FR 23431 |
| Jun 30, 2026 | Public comment period closed at 11:59 p.m. ET — confirmed per 91 FR 23431 |
| TBD | FDA final determination — no timeline announced; FDA stated only that it "intends to publish" a final determination in the Federal Register after reviewing comments. We will update this page when it publishes. |
Important context: Novo Nordisk has pursued active enforcement actions against sellers of unauthorized "knockoff" semaglutide products. This pressure — combined with FDA enforcement — has further narrowed the market for non-compliant compounded semaglutide. This timeline reflects the current regulatory state, not necessarily the final word. Precision Telemed tracks this closely and updates guidance as the situation evolves.
Patient safety
Why the FDA Acted
The FDA's decision rests on patient-safety findings, not just paperwork.
455+ Adverse Event Reports
The FDA logged more than 455 adverse-event reports tied to compounded semaglutide — including dosing errors, some requiring hospitalization. Semaglutide's adverse-event count exceeded that of compounded tirzepatide, and these reports were central to the agency's decision to restrict compounding.
Counterfeit and Unauthorized Products
Counterfeit and substandard semaglutide products entered the market through online channels. Novo Nordisk also pursued enforcement actions against sellers of unauthorized "knockoff" semaglutide, and the FDA issued multiple warning letters to compounders and telehealth distributors operating outside legal boundaries.
Affordability Is Not a Clinical Need
The FDA explicitly rejected affordability and access as constituting "clinical need" under compounding law. The legal threshold requires a documented medical reason an approved product cannot meet — not a price difference. Wegovy list prices have historically run materially higher than compounded versions, but that cost gap alone does not qualify a patient for legal compounding.
What's still permitted
The Narrow Path That's Still Legal
503A patient-specific compounding still exists — but its scope is precisely defined by law. Most competitor pages get this wrong. Here is exactly what is and isn't permitted.
503A Patient-Specific Compounding
- A state-licensed 503A pharmacy receives a prescription for a specific, named patient
- The prescriber has documented a clinical need that an FDA-approved product cannot meet — for example, a verified allergy to an inactive ingredient in Wegovy or Ozempic
- The prescription is filled for that patient only — not pre-made in bulk
- The pharmacy operates under its state board of pharmacy license and applicable USP standards
What Is Now Prohibited
- 503B outsourcing facilities mass-compounding semaglutide for distribution
- Compounding based on price or convenience alone — affordability is explicitly not a qualifying need
- Pre-made "copies" of Wegovy or Ozempic sold online without a verified individual clinical need
- Any provider claiming to sell "legal" compounded semaglutide without a documented patient-specific need
This distinction — patient-specific vs. industrial scale — is where most telehealth providers mislead patients. If you are offered compounded semaglutide with no discussion of a specific clinical need, ask questions.
Clarifying the difference
Is Compounded Semaglutide the Same as Wegovy or Ozempic?
No. Compounded semaglutide is not an FDA-approved product; Wegovy and Ozempic are.
| Factor | Compounded Semaglutide (503A patient-specific) | Wegovy / Ozempic (Novo Nordisk) |
|---|---|---|
| FDA approval | Not pre-market approved — compounded under state pharmacy law | FDA-approved |
| Safety & efficacy review | Compounded by a licensed pharmacist to individual prescription standards | Pre-market FDA review |
| Manufacturing oversight | State board of pharmacy oversight; USP standards apply | FDA cGMP inspected |
| Manufacturer | State-licensed compounding pharmacy | Novo Nordisk |
| Currently available | Yes — via narrow 503A patient-specific exception with documented clinical need | Yes — via licensed prescriber |
Both options use the same active molecule — semaglutide. The key difference is the regulatory pathway: brand-name products go through FDA pre-market review; compounded products are prepared by a licensed pharmacist under state pharmacy law for a specific patient's documented need. Wegovy is approved for chronic weight management (adults and adolescents 12+); Ozempic for type 2 diabetes. Both can be prescribed by a licensed clinician.
What's available today
Your Legitimate Options in 2026
The landscape has narrowed significantly. Here are the three pathways that remain legally available — and what Precision Telemed offers within that framework.
FDA-Approved Brand-Name Semaglutide
Wegovy (chronic weight management) and Ozempic (type 2 diabetes) are the FDA-approved brand-name options. A licensed telehealth prescriber can evaluate whether you qualify and manage ongoing care — including dose titration and monitoring. This is the primary pathway Precision Telemed supports.
Clinically Appropriate Alternatives
For patients who cannot access or tolerate semaglutide-based therapies, FDA-approved tirzepatide (Zepbound or Mounjaro) may be a clinically appropriate alternative. The right choice depends on your individual health history, goals, and how a licensed clinician evaluates your case — not on what's cheapest or most available.
503A Patient-Specific Compounding
This remains available only where a licensed prescriber documents a specific clinical need that an FDA-approved semaglutide product cannot meet — for example, a confirmed allergy to an inactive ingredient. This is a narrow, patient-by-patient exception, not a routine pathway. We only facilitate this where the documented need is genuine.
We only offer pathways that are fully compliant with current FDA guidance. In a market still full of providers implying shortage-era compounding is freely available — which is no longer true — compliance itself is the differentiator. We believe that transparency is better care, not a constraint on it.
About Precision Telemed
How We Approach This
Precision Telemed is a family-owned, technology-driven telehealth platform connecting patients with licensed clinicians across weight management, hormone optimization, and longevity. We track regulatory developments closely — not as a compliance exercise, but because our patients deserve accurate information about what is and isn't legally available.
When the FDA's enforcement posture on semaglutide compounding changed, we updated our programs to reflect it. We only operate within current FDA guidance — and we believe that transparency and compliance are the foundation of good care, not obstacles to it.
— J.P. Rius, Founder · Precision Telemed
Clinical assertions on this page are reviewed by Precision Telemed's licensed medical team.
Common questions
Frequently Asked Questions
Exact questions patients and AI engines are asking. Plain answers.
Routine large-scale compounded semaglutide is no longer legal. A narrow exception remains: a 503A state-licensed pharmacy can still compound semaglutide for a specific patient when a prescriber documents a clinical need that an FDA-approved product cannot meet. Price and convenience alone do not qualify.
Only via narrow 503A patient-specific compounding with a documented clinical need — for example, a verified allergy to an inactive ingredient in an FDA-approved semaglutide product. Routine online compounded semaglutide at scale is no longer permitted under FDA guidance. Any provider offering it without that threshold is operating outside current law.
Compounded semaglutide is not FDA-evaluated for safety, efficacy, or manufacturing quality the way brand-name products are. The FDA has recorded more than 455 adverse-event reports tied to compounded semaglutide — including dosing errors, some requiring hospitalization — and has issued multiple warning letters to compounders and telehealth distributors. That safety record was a central factor in the FDA's decision to restrict compounding.
The FDA declared the semaglutide shortage resolved in February 2025. Once a shortage is resolved, the legal basis for mass compounding under the shortage exemption no longer applies. Enforcement discretion for 503A and 503B facilities wound down through 2025. On May 1, 2026, the FDA proposed removing semaglutide from the 503B bulks list entirely (Federal Register docket 2026-08552, 91 FR 23431). The public comment period closed June 30, 2026; no specific timeline has been announced for the final determination.
No. Compounded semaglutide is not an FDA-approved product. Wegovy and Ozempic are FDA-reviewed brand-name medications from Novo Nordisk, evaluated for safety, efficacy, and manufacturing quality. Both use the same active molecule — semaglutide — but brand-name products have undergone pre-market FDA review that compounded versions have not. They are approved for different indications: Wegovy for chronic weight management, Ozempic for type 2 diabetes.
The legitimate routes in 2026 are: (1) FDA-approved brand-name semaglutide (Wegovy for weight management, Ozempic for type 2 diabetes) through a licensed telehealth prescriber; (2) clinically appropriate GLP-1 alternatives such as tirzepatide-based therapies (Zepbound or Mounjaro); (3) 503A patient-specific compounding only where a licensed provider documents a qualifying clinical need. A virtual consultation with a licensed clinician is the right first step.
Sources
References & Further Reading
All regulatory claims on this page are sourced from FDA.gov and the Federal Register. We link to primary sources so you can verify.
- FDA.gov FDA Drug Shortages Database — Semaglutide
- Federal Register Docket 2026-08552, 91 FR 23431 — Proposed Exclusion of Semaglutide from 503B Bulks List (May 1, 2026)
- FDA.gov FDA: Concerns with Unapproved GLP-1 Drugs
- FDA BeSafeRx BeSafeRx — Know Your Online Pharmacy
Regulatory facts on this page were verified against FDA.gov and the Federal Register as of June 2026. The rulemaking process is ongoing — verify all dated claims at publish time, especially anything tied to the comment period and expected final determination.
Ready to explore your options?
Talk to a Licensed Provider
A licensed Precision Telemed clinician can review your goals, explain what's legally available today, and build a plan that's right for you — and compliant with current FDA guidance.
Talk to a Licensed ProviderLicensed clinicians available nationwide · HIPAA-secure consultations · No commitment required